PROVIDERS /// INFECTIOUS DISEASE
We empower you with home collection kits sent directly to your eligible patients
With the rise in telehealth and the focus on keeping patients safe at home, we have made it easy to order a home collection kit and send it directly to an eligible patient. Both you and your patient will typically get results within 12-24 hours of the time Tempus receives the sample at its lab.
Contact UsOUR TESTING
Leveraging testing and clinical data against COVID-19
We are committed to using our advanced testing and analytics capabilities to support care management for COVID-19.
- Our Tempus Nasal Sample Collection Kit and SalivaDirect™At-Home Collection Kit are FDA EUA Authorized
- Sample is gathered through a gentle nasal swab or saliva collection
- Tempus will bill the applicable insurance program for testing and report results to applicable public health authorities
- Results are typically available within 12-24 hours after specimen receipt in our lab
- Easy-to-use portal for ordering
- Patients can quickly get results through the Tempus mobile app
GETTING STARTED
How to order a COVID-19 test through Tempus
Contact us to learn more or order a test- Provider orders a home collection kit for their eligible patient through our online portal. The applicable insurance program will be billed for the test and Tempus will handle required public health reporting.
- Eligible patient receives kit and self-administers sample collection at home. Overnight shipping is included to send the sample collection back to our lab.
- Provider receives patient's results. You and your patient will typically receive results within 12-24 hours.
FDA AUTHORIZATION
Tempus’ COVID-19 tests are either validated in accordance with FDA policies or have received an EUA authorization from FDA.
The EUA authorized test: has not been FDA cleared or approved; has been authorized by FDA under an EUA for use by the authorized laboratories; has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The SalivaDirect™ EUA authorized test: has not been FDA cleared or approved; has been authorized by FDA under an EUA for use by the authorized laboratories; has been authorized only for the collection and maintenance of saliva specimens as an aid in the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of medical devices under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.